Skip to main content

Table 2 Distribution of clinical parameters according to ERα/Src expression

From: Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant

Variable ERα/SRC ≤10, no. (%) ERα/SRC >10, no. (%) P*
Age groups ≤50 years 76 (29.7) 35 (20.1) 0.026
>50 years 180 (70.3) 139 (79.9)
T. size ≤2 cm 152 (59.4) 97 (55.7) 0.455
>2 cm 104 (40.6) 77 (44.3)
LN invasion No 108 (42.2) 74 (42.5) 0.944
Yes 148 (57.8) 100 (57.5)
SBR grade Gr 1 44 (17.2) 37 (21.3) 0.394
Gr 2 129 (50.4) 77 (44.3)
Gr 3 83 (32.4) 60 (34.5)
ERα status Negative 34 (13.3) 21 (12.1) 0.712
Positive 222 (86.7) 153 (87.9)
PR status Negative 61 (23.8) 47 (27.0) 0.455
Positive 195 (76.2) 127 (73.0)
HER2 status Negative 238 (83.7) 157 (91.3) 0.345
Positive 16 (6.3) 15 (8.7)
Breast Cancer subtype Luminal A 146 (57.0) 95 (54.6) 0.876
Luminal B 76 (29.7) 58 (33.3)
HER2 rich 7 (2.7) 4 (2.3)
TNBC 27 (10.5) 17 (9.8)
Type of adjuvant hormonal Tamoxifen 93 (42.3) 78 (52.3) 0.057
AI 127 (57.7) 71 (47.7)